# Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

> **NCT05101213** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Adenovirus Infection
- BK Virus Infection
- Cytomegaloviral Infection
- Hematopoietic and Lymphoid Cell Neoplasm
- JC Virus Infection
- Malignant Solid Neoplasm
- Symptomatic COVID-19 Infection Laboratory-Confirmed

## Interventions

- **BIOLOGICAL:** Virus-specific Cytotoxic T-lymphocytes

## Key facts

- **NCT ID:** NCT05101213
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-06
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101213, "Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05101213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*